Kezar Life Sciences, Inc. (KZR) Research

Kezar Life Sciences, Inc. is a United States-based clinical-stage biopharmaceutical company focused on identifying and advancing novel small molecule therapies. Its mission is to address significant unmet medical needs in both immune-mediated diseases and various forms of cancer. The company's most advanced experimental drug is KZR-616, a specialized immunoproteasome inhibitor. This candidate is currently undergoing Phase 2 clinical evaluation for several conditions, including lupus nephritis, dermatomyositis, and polymyositis. Concurrently, KZR-616 is also in Phase 1b clinical trials for systemic lupus erythematosus and lupus nephritis. In its preclinical pipeline, Kezar is developing KZR-261, a pioneering first-in-class protein secretion inhibitor, as well as KZR-TBD, which is being investigated for its potential in oncology and immunology. The firm was founded in 2015 and is headquartered in South San Francisco, California.

Market snapshot

Symbol
KZR
Price
$7.29
Day change
0.00%
Market cap
$53.9M
P/E ratio
-1.18x
52-week range
3.53-7.55
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$11.00

Peer companies

  • Aligos Therapeutics, Inc. (ALGS)
  • Actinium Pharmaceuticals, Inc. (ATNM)
  • Barinthus Biotherapeutics plc (BRNS)
  • FibroGen, Inc. (FGEN)
  • Mersana Therapeutics, Inc. (MRSN)
  • OnKure Therapeutics, Inc. (OKUR)
  • PDS Biotechnology Corporation (PDSB)
  • Tempest Therapeutics, Inc. (TPST)

Recent insider activity

  • Wallace Courtney — D-Return (3500 shares) on 2026-05-11
  • Wallace Courtney — D-Return (5000 shares) on 2026-05-11
  • Wallace Courtney — D-Return (5000 shares) on 2026-05-11
  • Wallace Courtney — D-Return (2600 shares) on 2026-05-11
  • Schiller Mark C. — U-Tender (2739 shares) on 2026-05-11

Open Kezar Life Sciences, Inc. (KZR) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.